Evoke Pharma — Investor Presentation (January 2017)
21 slides from Evoke Pharma's investor presentation, Jan 9, 2017
Slide 1: Evoke Pharma January 2017
NASDAQ: EVOK January 2017 Exh. 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about Evoke Pharma, Inc. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “beli
Slide 3: Investment Highlights
Investment Highlights Product Gimoti™: a novel nasal delivery of metoclopramide Symptomatic relief of acute and recurrent diabetic gastroparesis in women Differentiation versus Oral Medications Predictable absorption despite delayed and erratic stomach emptying Absorption not affected by vomiting La
Slide 4: Gastroparesis: Unpredictable & Difficult to Treat
Gastroparesis: Unpredictable & Difficult to Treat Delayed emptying of stomach contents to small intestine (in the absence of an obstruction) interferes with oral absorption Vomiting further complicates effectiveness of oral medications Symptoms characteristic of flare: Undissolved drug tablets in st
Slide 5: Gastroparesis: Large & Growing Market
Gastroparesis: Large & Growing Market Estimated $3-4B prescription market $3.5B in additional hospitalization costs in 2004 ~2-3M patients currently receive treatment Under-diagnosed in part due to lack of awareness Diabetes is number one known cause Increasing prevalence due to growing diabetes rat
Slide 6: Gastroparesis: Unmet Clinical Need
Gastroparesis: Unmet Clinical Need Motility & Symptoms Metoclopramide (1st line) Domperidone (not FDA-approved) Motility Erythromycin (not indicated) Symptoms Odansetron, promethazine (N & V) PPI’s (Abdominal pain) Narcotics (Abdominal pain) Current oral treatment options lack predictable delivery A
Slide 7: Study Shows Improved Efficacy with Non-Oral Treatment
Study Shows Improved Efficacy with Non-Oral Treatment “This non-oral route generates a constant plasma level of the metoclopramide when: Patients are vomiting Unpredictable absorption limits the value of any orally administered agent” Clinical study only: Subcutaneous metoclopramide not commercially
Slide 8: Gimoti: Our Treatment Solution
Gimoti: Our Treatment Solution Novel approach for symptomatic relief of acute & recurrent diabetic gastroparesis in women Unlike oral medications, nasal delivery bypasses the gastrointestinal tract and directly enters the bloodstream Provides predictable absorption regardless of gastric emptying del
Slide 9: Phase 3 Results & Design
Phase 3 Results & Design Efficacy Primary endpoint not met (N = 205, p = 0.881) Statistically significant results demonstrated in patients with moderate to severe gastroparesis symptoms at baseline at multiple time points Significant placebo effect in mild patients Safety Gimoti was well-tolerated S
Slide 10: Supplemental Analysis of Phase 3 Data
Supplemental Analysis of Phase 3 Data Patients with moderate to severe symptoms (N = 105, 51% of subjects) responded statistically significantly better to Gimoti than placebo Analysis of patients with higher symptom severity consistent with FDA Draft Guidance (July 2015) Population Time Period Place
Slide 11: Supplemental Efficacy Analysis of Phase 3 Data
Supplemental Efficacy Analysis of Phase 3 Data Symptom Time Period Placebo1 (N = 53) Gimoti1 (N = 52) p-value2 Nausea Week 1 -0.370 -0.859 0.001 Week 2 -0.696 -1.149 0.032* Week 3 -0.818 -1.242 0.043 Week 4 -0.905 -1.404 0.027 Upper Abdominal Pain Week 1 -0.394 -0.641 0.025 Week 2 -0.554 -0.990 0.01
Slide 12: Phase 2b Efficacy Results
Phase 2b Efficacy Results Summary of Phase 2b Study Statistically significant difference between Gimoti and placebo (p<0.02) for pre-specified analysis group of females (n=203) Results not significant for ITT population due to lack of statistical differentiation from placebo in males (n=84) Other Co
Slide 13: Gimoti: Well Tolerated in Clinical Trials
Gimoti: Well Tolerated in Clinical Trials Favorable Safety Profile in Phase 1 ,2, 3 and TQT studies No deaths, few SAE’s and no SAE’s related to study drug Dropouts Phase 2 = 10% (includes 5% due to AE) Phase 3 = 7% (includes 2% due to AE) TQT study: No QT prolongation at supratherapeutic dose (80 m
Slide 14: FDA guidance provided at Pre-NDA Meetings
FDA guidance provided at Pre-NDA Meetings Currently developing strategy for healthy volunteer pharmacokinetic (PK) study In discussions with Manufacturing organizations Phase I clinical study sites NDA development in parallel with PK trial Gimoti: Timeline Completed Phase 3 in women (METO-IN-003) Pr
Slide 15: Compelling Commercial Opportunity
Compelling Commercial Opportunity Significant Unmet Need Physicians and patients report broad interest in non-oral treatment alternatives to address unpredictable absorption No new therapies for gastroparesis since 1980 Ready-made Market 4M prescriptions of oral metoclopramide annually 20-50% of pat
Slide 16: Current Competitive Landscape
Current Competitive Landscape Product Class Route Company Development Status Gimoti Dopamine antagonist & mixed 5-HT3 antagonist/5-HT4 agonist Nasal Evoke Pharma Phase 3 (n=205): Statistical significance achieved in patients with moderate to severe gastroparesis. Did not meet primary endpoint for IT
Slide 17: Addressing Physician Concerns
Addressing Physician Concerns Source: ZS Associates Gastroparesis quantitative survey (n=121), Question 4Q5: How much do you agree with each of the following statements? Totals weighted based on average metoclopramide TRx’s per high/medium segment Completely Disagree Completely Agree
Slide 18: Strong Pricing Potential
Strong Pricing Potential Ample commercial insurance reimbursement expected Prices similar to ($B) or higher than ($H) than current branded GI products Similar regardless of label (profile) differentiation Mostly Tier 3 “Unrestricted” or “Restricted” coverage projected (typical for branded products)
Slide 19: Summary: Long-Term IP Protection
Summary Current patents provide protection against: Delivering metoclopramide into the nose to treat symptoms associated with gastroparesis; and Using a spectrum of stable liquid formulations containing metoclopramide Long-Term IP Protection U.S. Granted Patents Patent # U.S. 6,770,262 U.S. 8,334,28
Slide 20: Selected Financial Data
Selected Financial Data Income Statement Data (in USD) Cash (in USD) and Equity Data 3Q 2016 (Ended September 30, 2016) Operating Expense Research & Development $1.3M General Administrative $0.8M Total Operating Expense $2.1M Other (Income) Expense $0.8M Net Loss $3.0M September 30, 2016 Cash Balanc
Slide 21: Investment Highlights
Gimoti™: novel nasal delivery of metoclopramide for the symptomatic relief of acute and recurrent diabetic gastroparesis in women Only one FDA-approved therapy for gastroparesis: Metoclopramide (oral & IV) which has ~4M million prescriptions of the oral medication annually Serves unmet clinical need